Enexor Granted FDA Emergency Use Authorization for New Ventilator – X-VENT

VERITAS Vision System Is Introduced by Johnson & Johnson

The company will offer live demos of the new system in a wet lab at the Johnson & Johnson booth (#2813) this weekend at the 2021 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting.

GenesisCare Orders 27 Elekta Flexitron Treatment Devices

"GenesisCare continues to demonstrate its commitment to improving patient outcomes worldwide and Elekta is delighted to play a vital partnering role to achieve this mission," said Gustaf Salford, Elekta's President and CEO.

FoodMarble AIRE Shown to Exceed the Performance of ‘Gold Standard’ SIBO Testing in Clinical Trial

SIBO is a very common disorder where there are excessive bacteria present in the small intestine. The true prevalence of SIBO in the general population is largely unknown, with some studies estimating its occurrence in up to 15% of healthy individuals. It is also largely associated with many other common clinical conditions, including irritable bowel syndrome, where 40-80% of IBS patients have SIBO.

June 17, 2020

Enexor reported today that the U.S. Food and Drug Administration has granted an Emergency Use Authorization for the immediate delivery and use of a new ventilator, the X-VENT.

Enexor will start delivering ventilators to hospitals within a few days.

Guided by the medical team of physicians and respiratory therapists, led by Dr. Bill Walsh of Vanderbilt University’s Monroe Carrol Jr Children’s Hospital, a pioneer in ventilation technology and one of the design team members of the original oscillating ventilator, the X-VENT was designed to deliver the critical modes of ventilation required for COVID patients.  “The X-VENT is a sophisticated, complex, state-of-the-art ventilator capable of providing multiple modes of mechanical ventilation. The engineers did an amazing job keeping it simple, easy to use, and inexpensive. It is exactly what the physicians of the world need to support their patients through acute respiratory failure.” states Dr. Bill Walsh.

The X-VENT is one of the very few FDA EUA approved ventilators that does not use a bag valve mask (BVM) resuscitator (often referred to colloquially by the proprietary name “Ambu-bag”).  The X-VENT utilizes a piston-driven air system controlled by a Schneider Electric industrial-grade programmable logic computer (PLC). The system is designed for many years of use, and is self-calibrating, so it can easily be stored.  The X-VENT is priced significantly below the cost of a traditional ventilator to encourage worldwide use to impact more lives.

Enexor has leveraged its extensive engineering design, manufacturing, and operational capabilities to quickly design, test and manufacture the unique ventilator.  “Enexor was created to help solve major world problems. In responding to COVID and future pandemics, we stayed true to our mission by putting together an incredible team of medical professionals, engineers and manufacturing specialists with the ultimate mission of designing and manufacturing a durable, reliable, easy to maintain, and affordable ventilator that can be deployed at any hospital in the world to help save lives.  The team delivered with the X-VENT.”, states Jestings.

Enexor has already begun manufacturing ventilators. With the FDA approval, Enexor will ramp up manufacturing to meet the critical needs in the U.S. and internationally.

spot_img

DON'T MISS

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.